Business
Pre-close trading update
Fever-Tree Drinks plc anticipates its 2025 financial performance to be marginally ahead of market expectations, with adjusted revenue and adjusted EBITDA expected to exceed forecasts. The company reported 5% revenue growth for the Fever-Tree brand in the second half of 2025, contributing to a full-year constant currency growth of 4%. The US market showed a 6% constant currency revenue increase, supported by the transition to Molson Coors' distribution network, while the UK saw a 2% decline. Following a £100 million share buyback in 2025, an additional £30 million tranche is planned for February 2026. Disclaimer*
About this update from Fevertree Drinks Plc
[{"type":"text","content":"\n\n\nFever-Tree Drinks plc\n\n\"Excellent strategic progress in 2025 and expect to deliver a financial performance\nmarginally ahead of market expectations.\"\n \nFever-Tree Drinks plc (the \"Group\"), the world's leading supplier of premium carbonated mixers, today provides a pre-close trading update for the year ended 31 December 2025.\n \nAdjusted revenue1 and adjusted EBITDA2 for FY25 are expected to be marginally ahead of current market expectations3, based upon good momentum in the second half which has resulted in Fever-Tree brand revenue increasing by 5% in H2, and full year growth of 4% (both at constant currency). This reflects continued delivery against the Group's strategic priorities and ongoing strong market share performance. In the US, the transition into Molson Coors' national distribution network is progressing to plan and, alongside an upweighted marketing investment, will provide a strong platform for 2026.\n \nFollowing the £100m share buyback programme undertaken during 2025, the previously announced additional £30m share buyback tranche will commence in February 2026.\n \n\n\n\n\n£m\n\n\nFY25\n£m\n\n\nFY24\n£m\n\n\n% change\n \n\n\n% change (CC)*\n\n\n\n\n US\n\n\n131.9\n\n\n128.0\n\n\n3%\n\n\n6%\n\n\n\n\n UK\n\n\n108.4\n\n\n111.1\n\n\n(2%)\n\n\n\n\n\n\n\n Europe Fever-Tree brand revenue\n\n\n94.7\n\n\n92.7\n\n\n2%\n\n\n2%\n\n\n\n\n ROW\n\n\n37.7\n\n\n32.2\n\n\n17%\n\n\n22%\n\n\n\n\nTotal Adjusted Fever-Tree Revenue1\n\n\n372.7\n\n\n364.0\n\n\n2%\n\n\n4%\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n GDP brand revenue\n\n\n2.6\n\n\n4.5\n\n\n(42%)\n\n\n(43%)\n\n\n\n\nTotal Adjusted Revenue\n\n\n375.3\n\n\n368.5\n\n\n2%\n\n\n3%\n\n\n\n\n*Constant Currency (CC).\n1. Adjusted Revenue is statutory reported revenue adjusted to bring US revenue in line with invoiced sales to customers.\n2. Adjusted EBITDA is earnings before interest, tax, depreciation, amortisation, share-based payment charges, exceptional items and finance costs. As disclosed in September 2025, the Company has not provided for certain costs related to UK Extended Producer Responsibility levy, and continues to engage with the Environment Agency on the same.\n3. Company collated consensus FY25 adjusted revenue £372.4m and adjusted EBITDA £44.4m. FY26 adjusted revenue consensus £409.4m (current r...